Management of Hyperprolactinemia in Clinical Practice
DOI:
https://doi.org/10.56056/amj.2023.221Keywords:
Clinical Practice, Hyperprolactinemia, ProlactinomaAbstract
Background & objectives: Hyperprolactinemia is defined as an increased prolactin level above the normal reference range, in women more than 25 ng/dl; with a prevalence rate of 10% in the general population. Hyperprolactinemia is associated with different clinical presentations various from oligomenorrhea, amenorrhea, galactorrhea, and infertility. This study aims to be to assess the current practice regarding the management of hyperprolactinemia in non-pregnant women in the Kurdistan region, Iraq.
Subjects and Methods: An electronic questionnaire on current practice concerning diagnosis and treatment of hyperprolactinemia in non-pregnant women was sent through e-mail to 167 clinicians, 166 of them completed the survey and they were from different cities (Duhok, Sulaymaniyah, Erbil, and Halabja) of the Kurdistan region, Iraq.
Results: A total of 166 valid questionnaires were collected. The response received from 166 clinicians. Almost 97 % of the responders were asking about the presence of symptoms of prolactinoma in patients with hyperprolactinemia and the majority of responders were made an exclusion of physiological causes related to hyperprolactinemia. When hyperprolactinemia occurred, only 81.3% of the respondents would test for thyroid-stimulating hormone routinely. Majority of the responders (79.5%) did not confirm the biochemical diagnosis of hyperprolactinemia before starting treatment and only two-thirds of them do pituitary imaging. Also, our results show an important role of clinician’s characteristics like age group on the management outcome, as the age group 25-35 was better when compared to the age group 46-55 (p-value =0.044) and the internist specialty and family medicine specialty have a better impact on management outcome in comparison to endocrinologist with (p-value =0.046 and 0.043 respectively).
Conclusions: We found that the current clinical practice for the management of hyperprolactinemia is not uniform with some scientific defects. Therefore, it is necessary to develop national guidelines for the management and treatment of hyperprolactinemia.
Downloads
References
Grattan DR, Kokay IC. Prolactin: a pleiotropic neuroendocrine hormone. J Neuroendocrinol. 2008; 20: 752-63.
Fritz M, Speroff L. Hormone biosynthesis, metabolism, and mechanism of action. In: Fritz MA, Speroff L, editors. Clinical gynecologic endocrinology and infertility. 8th ed. Philadelphia: Lippincott Williams & a Wolters Kluwers Bussiness; 2011: 29e105.
Saleem M, Martin H, Coates P. Prolactin biology and laboratory measurement: an update on physiology and current analytical issues. Clin Biochem Rev. 2018; 39(1):3-16.
Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. 2001; 30:585-610.
Bronstein MD. Disorders of prolactin secretion and prolactinomas. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 6th ed. Philadelphia: Saunders/Elsevier. 2011; 333-57.
Mah P, Webster J. Hyperprolactinemia: etiology, diagnosis, and management. Semin Reprod Med. 2002. 20(4):365-74.
Le Tissier PR, Hodson DJ, Martin AO, et al. Plasticity of the prolactin (PRL) axis: mechanisms underlying regulation of output in female mice. Recent Advances in Prolactin Research. 2015; 846: 139-62.
Vilar L, Abucham J, Albuquerque JL et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018; 62(2): 236–63.
Glezer A, Bronstein MD. Approach to the patient with persistent hyperprolactinemia and negative sellar imaging. J Clin Endocrinol Metab. 2012; 97(7): 2211–6.
Mancini T, Casanueva F, Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am. 2008; 37(1): 67–99.
Ciccarelli A, Daly A, Beckers A. The epidemiology of prolactinomas. Pituitary. 2005; 8(1): 3–6.
Serri O, Chik C, Ur E, Ezza S. Diagnosis and management of hyperprolactinemia. CMAJ. 2003; 169 (6), 575-81.
Yuen B. Etiology and treatment of hyperprolactinemia. Seminars in Reproductive Medicine. 1992; 10(03):228–35. .
Vroonen L, Daly A, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019: 109:20–7
Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017: 317: 516-24.
Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population-based study in Malta. Pituitary. 2013:16: 545-53.
Buurman H, Saeger W. Subclinical adenomas in postmortem pituitaries: classification and correlations to clinical data. Eur J Endocrinol. 2006: 154:753–8
Glezer A, Bronstein MD. Prolactinomas in pregnancy: considerations before conception and during pregnancy. 2020; 23(1):65-9. doi: 10.1007/s11102-019-01010-5
Whitehead S, Cornes M, Ford C, Gama R. Reference ranges for serum total and monomeric prolactin for the current generation Abbott Architect assay. Ann Clin Biochem 2015: 52: 61-6.
Molitch ME. Disorders of prolactin secretion. Endocrinol Metab Clin North Am. 2001; 30(3): 585–610.
Bronstein MD. Disorders of prolactin secretion and prolactinomas. In: DeGroot LJ, Jameson JL, editors. Endocrinology. 6th ed. Philadelphia: Saunders/Elsevier. 2010:333–57.
Asa S, Ezzat S. The Pathogenesis of Pituitary Tumors. Nat Rev Cancer. 2002; 2: 836-49.
Melmed S, Casanueva F, Hoffman A, et al Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011; 96(2): 273–88
Nunesa, V, Vicentini H, Padovanic C, Nogueira C. Electronic survey of management of hyperprolactinemia in Brazil: Endocrinologists versus gynecologists revargent endocrinol metab. 2017; 54(3):124–9.
Melmed S, Jameson J. Disorders of the Anterior Pituitary and Hypothalamus. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw Hill; 2008: 2076-97.
Iglesias P, Díez J. Macroprolactinoma: a diagnostic and therapeutic update. QJM 2013: 106: 495-504.
Verges B, Boureille F, Goudet P, et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab. 2002: 87: 457-65.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Bayar Ahmed Qasim, Kajeen Rashid Hussein, Mazyar Jabbar Ahmed, Sherwan Ferman Salih, Mohammed Aziz Sulaiman
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The copyright on any article published in AMJ (The Scientific Journal of Kurdistan Higher Council of Medical Specialties )is retained by the author(s) in agreement with the Creative Commons Attribution Non-Commercial ShareAlike License (CC BY-NC-SA 4.0)
